AUA 2018: Comparative Analysis of Perioperative Outcomes for Patients With 4-7cm RCC Treated with Either Microwave Ablation, Partial Nephrectomy or Radical Nephrectomy

San Francisco, CA USA ( Daniel D. Shapiro of the University of Wisconsin School of Medicine and Public Health delivered a podium on their study looking at perioperative outcomes in patients with 4 – 7 cm renal cell carcinoma (RCC) tumors treated with either microwave ablation (MWA) or nephrectomy.

AUA 2018: Exploration of Biomarkers Associated with Prognosis in Patients with Clear Cell Renal Cell Carcinoma Undergoing Surgical Resection by Desorption Electrospray Ionization Imaging Mass Spectrometry

San Francisco, CA USA ( Mr. Keita Tamura, clinical research urology associate from Hamamatsu University School of Medicine, presented data that evaluated the efficacy of a novel molecular anatomy technique, desorption electrospray ionization imaging mass spectrometry (DESI-IMS), to identify biomarkers from a range of lipids from and to predict the prognosis of patients with clear cell renal cell carcinoma (ccRCC). As an introduction, Mr. Tamura stated how although conventional mass spectrometry analysis is widely used to screen small biomolecules, it cannot distinguish between non-cancerous and cancerous tissues and produces false positives.

AUA 2018: Metabolomic Signatures in Urine from Renal Cell Carcinoma Patients

San Francisco, CA USA ( Annelise Bonvillain, MD, clinical research urology specialist from Emory University School of Medicine, presented data that evaluated if there were significant differences in the metabolomics of urine for patients with renal cell carcinoma (RCC). As an introduction, Ms. Bonvillain stated that RCC is the 7th most common cancer in men and 9th most common cancer in women in the US. The 5-year overall survival rate is less than 11.7%; however, early detection concurrent with conventional therapies exhibited 5-year survival rates of 92.5%.

AUA 2018: Estrogen Receptor β Promotes Renal Cell Carcinoma Progression via Regulating LncRNA HOTAIR-miR-138/200c/204/217 Associated CeRNA Network

San Francisco, CA USA ( relationship between the estrogen receptor and many known hormone-sensitive tumors has been identified, but the relationship of that and renal tumors has not been clearly observed. This clinical study presented by Jie Ding, MD, a urology specialist of the University of Rochester Medical Center, composed of the effect of over expressions and knockout of the estrogen receptor beta and the survival rate of patients with RCC. Although there was already identification between the regulatory relationship between the alpha and beta receptor,

AUA 2018: Use of Urinary Metabolomics to Identify High-Risk Clear Cell Renal Cell Carcinoma

San Francisco, CA USA ( Mohit Gupta, MD, a urologic oncologist at John Hopkins University of Medicine, presented a study regarding metabolomic markers that may identify and differentiate high-risk clear cell RCC from benign tumors. Dr. Gupta began the presentation by introducing the importance of metabolomics to identify discrepancies within current pathways known to urologic oncology. Although these pathways have been studied and used for different types of cancers, specific markers within urine of patients with ccRCC have not been clearly identified.

AUA 2018: Clinicopathological and Survival Analysis of Stage III/IV Papillary and Chromophobe Renal Cell Carcinoma: Implications for Future Clinical Trials

San Francisco, CA ( While clear cell histology remains the predominant histologic subtype of renal cell carcinoma, there remains a clinically significant proportion of patients who have papillary (type 1 and 2) and chromophobe histology. These histologic subtypes can have drastically different local and distance oncologic outcomes and, unfortunately, are rarely considered in clinical trials. Management is often inferred from trials treating clear cell histology predominantly. 

AUA 2018: Brain Metastasis from Renal Cell Carcinoma: An Institutional Study

San Francisco, CA ( Metastatic spread in renal cell carcinoma (RCC) often goes to the lungs and bones, and less commonly to the liver and brain. Prior studies1 have examined the spread of RCC utilizing population based analyses, and identified predictors of metastatic spread based on clinical features and histology. In this abstract, the authors use their institutional data to specifically focus on RCC related brain metastases, a relatively rare presentation. 

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.